CD274 and colorectal cancer: In the work presented here, we dissect the functional consequences of mutations at amino acid position 88 of PD-L1 that have been acquired in colorectal cancer patients across two clinical trials including the PD-L1 antibody avelumab as part of their experimental protocol.